Lilly to acquire Merida Biosciences in deal worth up to $2.875bn
The acquisition is to advance treatments for serious autoimmune and allergic diseases
Read More
Section: Sales
LEO Pharma acquires rights for dersimelagon from Tanabe Pharma
The company will pay $435m in up front and near-term milestone payments
Read More
Lilly to acquire AtaiBeckley in deal worth $2.8bn
The acquisition will advance therapies for treatment-resistant depression and other mental health conditions
Read More
AstraZeneca agrees on $1.5bn deal with Dizal Pharmaceutical
The company will gain a novel oral treatment for lung cancer
Read More
Ipsen to acquire Memo Therapeutics in deal worth more than €700m
The deal expands the company’s rare disease portfolio
Read More